Pickleball After Chemo: The Future of Cancer Treatment with Dr. Brandon Mancini
7 hours ago
- Theranostics represents a new era of precision medicine—highly targeted radiopharmaceuticals attack cancer at the molecular level while sparing healthy tissue, often with excellent tolerability.
- Patients with rare cancers like solitary fibrous tumors can benefit from emerging FAP-targeted trials and should explore clinical trial options and specialized centers.
- The field is advancing rapidly: centralized expertise, more trials, and earlier intervention are expanding access and improving outcomes across many tumor types.
Comments